SOPHiA GENETICS SA Company Profile

Background

Company Overview

SOPHiA GENETICS SA is a Swiss-founded health technology company specializing in data-driven medicine. Established in 2011 by Dr. Jurgi Camblong, Prof. Lars Steinmetz, and Dr. Pierre Hutter, the company is headquartered in Rolle, Switzerland, with additional offices in Boston, Massachusetts, and France. SOPHiA GENETICS provides an AI-powered platform that analyzes complex health data, including genomics, radiomics, and clinical records, to deliver actionable insights for patients with cancer and rare diseases. The platform is utilized by over 780 healthcare institutions worldwide, processing more than 350,000 patient cases annually.

Mission and Vision

SOPHiA GENETICS aims to democratize data-driven medicine by transforming complex health data into actionable insights, thereby improving patient care globally. The company's vision is to build a future where each patient has equal access to world-class care, leveraging AI and data analytics to personalize treatment plans.

Industry Significance

As a leader in the field of data-driven medicine, SOPHiA GENETICS plays a pivotal role in advancing precision medicine. By integrating AI with healthcare data, the company enhances diagnostic accuracy, accelerates drug discovery, and contributes to the global effort in combating complex diseases.

Key Strategic Focus

Core Objectives

Data Integration: Combining genomics, radiomics, and clinical data to provide comprehensive patient insights.

Global Expansion: Extending the reach of the SOPHiA DDM™ platform to healthcare institutions worldwide.

Innovation in Diagnostics: Developing AI-driven solutions to improve diagnostic precision and treatment personalization.

Areas of Specialization

Genomic Analysis: Interpreting complex genomic data to inform clinical decisions.

Radiomic Analysis: Utilizing medical imaging data to assess disease characteristics.

Clinical Data Integration: Combining various data types to enhance patient care.

Key Technologies Utilized

AI and Machine Learning: Employing advanced algorithms to analyze multimodal health data.

Cloud Computing: Utilizing scalable cloud infrastructure for data processing and storage.

Data Analytics Platforms: Developing platforms capable of handling large-scale health data.

Primary Markets Targeted

Healthcare Institutions: Hospitals and laboratories seeking advanced diagnostic tools.

Biopharmaceutical Companies: Organizations involved in drug discovery and development.

Research Organizations: Entities conducting studies in genomics and precision medicine.

Financials and Funding

Funding History

SOPHiA GENETICS has raised a total of $248.81 million across eight funding rounds. Notable investors include Credit Suisse, Hitachi, and Eurazeo. The most recent funding round was a Series F round in October 2020, raising $110 million.

Recent Funding Rounds

Series F (October 2020): $110 million raised.

Series E (January 2019): $77 million raised.

Notable Investors

Credit Suisse: A global financial services company.

Hitachi: A multinational conglomerate company.

Eurazeo: A global investment company.

Utilization of Capital

The funds have been allocated towards expanding the platform's capabilities, enhancing AI algorithms, and supporting global expansion efforts. Additionally, investments have been directed towards strategic partnerships and collaborations to strengthen the company's market position.

Pipeline Development

Key Pipeline Candidates

SOPHiA DDM™ Platform: An AI-driven platform analyzing multimodal health data to provide actionable insights.

Stages of Development

Clinical Trials: The platform is utilized in clinical settings for diagnostic support and treatment planning.

Product Development: Continuous enhancement of AI algorithms and data integration capabilities.

Target Conditions

Cancer: Including various types such as breast, lung, and colorectal cancers.

Rare Diseases: Conditions with limited treatment options and diagnostic challenges.

Anticipated Milestones

Global Expansion: Increasing the number of healthcare institutions using the platform.

Regulatory Approvals: Obtaining certifications and approvals in new markets.

Product Enhancements: Releasing updated versions of the platform with advanced features.

Technological Platform and Innovation

Proprietary Technologies

SOPHiA DDM™ Platform: An AI-powered platform for analyzing complex health data.

Significant Scientific Methods

Multimodal Data Analysis: Integrating genomics, radiomics, and clinical data for comprehensive insights.

AI and Machine Learning Algorithms: Developing algorithms to interpret complex datasets and provide actionable insights.

Leadership Team

Key Executives

Dr. Jurgi Camblong: CEO and Co-founder. Dr. Camblong has a background in biophysics and has been instrumental in developing the company's AI-driven platform.

Ross Muken: President. Mr. Muken oversees global business operations and strategic planning, bringing a strong background from his time as a leading healthcare equity research analyst.

George Cardoza, M.B.A.: Executive VP & Chief Financial Officer (CFO). Mr. Cardoza joined in November 2024, bringing over 30 years of experience in precision medicine and clinical diagnostics to manage the company's financials.

Abhimanyu Verma: Senior VP & Chief Technology Officer (CTO).

Zhenyu Xu: Executive VP & Chief Scientific Officer (CSO).

Leadership Changes

November 2024: Ross Muken was promoted to President.

November 2024: George Cardoza joined as Executive VP & CFO.

Competitor Profile

Market Insights and Dynamics

The precision medicine market is experiencing significant growth, driven by advancements in genomics, AI, and data analytics. The increasing adoption of AI in healthcare is enhancing diagnostic accuracy and treatment personalization.

Competitor Analysis

Illumina Inc.: A leading company in next-generation sequencing and array-based solutions.

Thermo Fisher Scientific: Offers a wide range of products and services, including genetic testing and bioinformatics solutions.

Tempus: Focuses on real-world data and AI-powered insights, particularly in oncology.

Foundation Medicine (Roche): Provides comprehensive genomic profiling assays.

Strategic Collaborations and Partnerships

AstraZeneca: In 2025, SOPHiA GENETICS secured a multi-year AI breast cancer partnership with AstraZeneca, demonstrating the platform's value in drug discovery and development.

Memorial Sloan Kettering Cancer Center: Committed to a collaboration to advance predictive tumor analysis and clinical decision support.

Operational Insights

SOPHiA GENETICS differentiates itself through its comprehensive AI-driven platform that integrates multimodal data, providing a holistic view of patient health. The company's global network of healthcare institutions enhances its data repository, improving the accuracy and applicability of its AI models.

Strategic Opportunities and Future Directions